drug
Enstilar
Marketedupdated 6mo agoby Perrigo New York Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Enstilar
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 27, 2027
335 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Mar 18, 2039formulationUS 11696919
- Mar 18, 2039formulationUS 12440499
- Dec 10, 2031patentUS 10130640*PED
- Dec 10, 2031patentUS 9119781*PED
- Jun 10, 2031formulationUS 101306404.6y
- Jun 10, 2031formulationUS 106176984.6y
- Jun 10, 2031formulationUS 106609084.6y
- Jun 10, 2031formulationUS 106823644.6y
- Jun 10, 2031method-of-use (U-2627)US 106881084.6y
- Jun 10, 2031formulationUS 107167994.6y
- Jun 10, 2031formulationUS 91197814.6y
- Jun 10, 2031formulationUS 95662864.6y
- Sep 27, 2027formulationUS 10265265335d
News(1)
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that